In vitro and in vivo antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and related compounds.
BV-araU and related compounds such as CV-araU, IV-araU and BV-araUMP showed marked activity against herpes simplex virus type 1 (HSV-1) in human embryonic lung fibroblast cells. BV-araU, CV-araU and BV-araUMP were also effective in mice infected intracerebrally with HSV-1. Especially, when mice were infected with a low dose of virus, both intravenous and oral treatment with BV-araU proved capable of increasing the mean survival time and decreasing the final mortality of the infected mice. The in vivo anti-HSV-1 activity of BV-araU was comparable to that of BVDU. BV-araU exhibited little toxicity for mice.
D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D004660:Encephalitis / Q000188:drug therapy; D006561:Herpes Simplex / Q000188:drug therapy; D008297:Male; D051379:Mice; D018139:Simplexvirus / Q000187:drug effects; D014529:Uridine / Q000031:analogs & derivatives*
D000998:Antiviral Agents; D001086:Arabinofuranosyluracil; C031368:sorivudine; D014529:Uridine